Enable Injections Names New Chief Commercial Officer To Leadership Team

As Enable Injections continues to develop and prepare for future commercial success, recent leadership changes and partnership announcements reflect our commitment to commercial growth and supporting our partners with the increasing product demand of enFuse^®.

New Chief Commercial Officer: Matt Huddleston

Previously Executive Vice President and Chief Technology Officer at Enable, Matthew Huddleston has been appointed Chief Commercial Officer of Enable Injections, responsible for leading marketing and business development operations as well as expanding commercial infrastructure to prepare for commercial launch and success of enFuse combination products. To support the ongoing clinical and commercial supply of the enFuse technology, Enable also recently announced plans to expand manufacturing operations with a new large-scale facility as well as enhance current corporate headquarters.​

Expanded Partnership with Roche

Enable Injections recently announced that we have expanded our partnership with Roche through a collaboration, allowing Roche to develop and apply Enable's expertise and enFuse platform to specific Roche development programs. Roche will obtain a worldwide, exclusive license to develop and commercialize combinations of the enFuse technology with specific Roche molecules.​

New Partnership with Serina Therapeutics

Enable announced a new collaboration with Serina Therapeutics to develop a potential enFuse combination product for advanced Parkinson's disease. Serina's investigational apomorphine therapy, in combination with enFuse, has the potential to significantly reduce many of the burdens associated with the current standard of care for Parkinson's patients.​

Meet with us at ASCO and BIO

Enable Injections will be exhibiting at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting June 1-3. Come visit us at IH05!

Enable will also be at the 2024 BIO International Convention June 3-6 and would love to answer questions as well as demonstrate our innovative enFuse technology. 

To learn more or to set up a meeting, please contact us.​​​​​​